For the millions who recovered from COVID-19 only to find themselves stranded in a fog of fatigue, confusion, and breathlessness, medicine has long offered names without explanations. Now, researchers from Mount Sinai, UC San Francisco, and Monogram Biosciences have traced a biological signature in the blood of long COVID patients — elevated inflammatory molecules that persist and even intensify long after the virus itself has gone. It is a finding that transforms a mystery of suffering into a question science knows how to pursue.
Study identifies immune markers linked to long COVID development
Approximately 10-40% of COVID-19 survivors experience long COVID with persistent symptoms including fatigue, cognitive impairment, and shortness of breath.
The immune system remains activated, continuing to produce inflammatory signals weeks and months after the virus itself has been cleared.
Mark
So the study found that people who develop long COVID have higher levels of these inflammatory markers. Does that mean the inflammation is causing the symptoms, or is it just correlated?
Mimi
That's the crucial question the study can't fully answer yet. What they've shown is an association—people with long COVID have these elevated markers, and people without it don't. But correlation isn't causation. The inflammation could be driving the symptoms, or it could be a side effect of whatever is actually driving them.
Luke
Right, and we should be careful about the language here. This is a preprint, not peer-reviewed. The sample is 121 people, which is real data but not huge. And the differences, while consistent, are in the range of 14 to 44 percent—meaningful, but not orders of magnitude.
Mark
What about the timeline? They measured early recovery and late recovery. Did the markers predict who would get long COVID?
Mimi
That's what's interesting. The elevated markers showed up in early recovery—within the first 90 days—in people who later developed long COVID. So there's a predictive element. If you had high IL-6 early on, you were more likely to still be symptomatic months later.
Luke
But again, we're talking about averages and trends. Some people with high early markers probably recovered fine. Some with lower markers probably didn't. The study doesn't give us individual-level prediction yet.
Mark
And therapeutically, what does this actually mean? Can you just lower these markers and fix long COVID?
Mimi
That's the hope, but it's speculative at this point. The researchers are saying these could be therapeutic targets—you could theoretically use drugs to dampen IL-6 or TNF-alpha. But whether that would actually relieve symptoms in long COVID patients? That hasn't been tested.
Luke
And there's a deeper question: if you lower the inflammation, are you treating the disease or just masking a symptom? We don't know if the inflammation is the root cause or the body's response to something else that's still broken.
Mark
So this is a map, not a cure.
Mimi
Exactly. It's a map of the immune landscape in long COVID. It tells us where to look next, but it doesn't tell us what we'll find when we get there.
Le Pouls
- Between 10 and 40 percent of COVID-19 survivors cannot return to normal life, enduring fatigue, cognitive fog, and breathing difficulties for months after infection — a scale of ongoing illness that medicine has struggled to explain.
- Tracking 121 patients through recovery, researchers identified three inflammatory markers — TNF-alpha, IP-10, and IL-6 — running significantly higher in those who would go on to develop long COVID, with IL-6 levels still climbing 44 percent above normal at four months post-infection.
- At the late recovery checkpoint, 60 percent of participants still reported symptoms, with memory problems, fatigue, and shortness of breath emerging as the dominant pattern — not outliers, but the majority experience.
- The leading hypothesis is that the immune system, rather than standing down after clearing the virus, remains in a state of sustained activation — continuing to fire inflammatory signals that may themselves be generating the ongoing symptoms.
- The findings, though preliminary and not yet peer-reviewed, point toward specific drug targets — IL-6 and TNF-alpha pathways already familiar to medicine — offering a concrete direction for therapies where none previously existed.
For the millions who recovered from COVID-19 only to find themselves stranded in a fog of fatigue, confusion, and breathlessness, medicine has long offered names without explanations. Now, researchers from Mount Sinai, UC San Francisco, and Monogram Biosciences have traced a biological signature in the blood of long COVID patients — elevated inflammatory molecules that persist and even intensify long after the virus itself has gone. It is a finding that transforms a mystery of suffering into a question science knows how to pursue.
Between one in ten and four in ten people who recover from COVID-19 find themselves unable to return to normal life — months after the acute infection, still caught in exhaustion, cognitive fog, and breathlessness. Long COVID has afflicted millions worldwide, yet its biological cause has remained elusive. Doctors could describe it; they could not explain it.
A research team from Mount Sinai, UC San Francisco, and Monogram Biosciences set out to change that by following 121 people with confirmed coronavirus infections through their recovery. They measured inflammatory markers in blood plasma at two windows: early recovery within the first 90 days, and late recovery beyond that. What emerged was a clear biological signature separating those who would develop long COVID from those who would not.
Three inflammatory molecules stood out. TNF-alpha ran 14 percent higher in early recovery among future long COVID patients. IP-10 was elevated by 28 percent. Most strikingly, IL-6 climbed 29 percent higher in early recovery — and kept rising. By late recovery, IL-6 levels in long COVID patients had surged to 44 percent above those who had fully healed.
At the late recovery checkpoint — a median of 124 days after infection — 60 percent of participants still reported ongoing symptoms. Memory and concentration problems affected 57 percent; fatigue, 56 percent; shortness of breath, 38 percent; loss of smell, 37 percent. These were not rare complaints. They were the dominant pattern.
The researchers' interpretation points to mechanism: in most people, the immune storm triggered by COVID-19 resolves. In long COVID patients, something different appears to happen — the immune system remains activated, continuing to produce inflammatory signals long after the virus has been cleared. That persistent activation, the team hypothesized, may be the engine behind the ongoing illness.
The practical implication is significant. If sustained inflammation is the driver, then targeting specific pathways — particularly IL-6 and TNF-alpha, molecules already familiar to pharmacology — could offer a therapeutic route for millions still trapped in this secondary illness. The study remains preliminary, posted on a preprint server and not yet peer-reviewed, and causation has not been proven. But for a condition that has confounded medicine and left its sufferers without answers, it represents something concrete: a measurable difference, a named pathway, and a direction forward.
Between one in ten and four in ten people who recover from COVID-19 find themselves unable to return to normal life. Months after the acute infection has passed, they remain trapped in a state of persistent exhaustion, cognitive fog, breathing difficulties, and sensory loss. This condition—long COVID, or post-acute sequelae of SARS-CoV-2 infection—has afflicted millions globally, yet until recently, the biological machinery driving it remained opaque. Doctors could name the symptoms but not the cause.
A team of researchers from Mount Sinai in New York, the University of California in San Francisco, and Monogram Biosciences set out to map the immune landscape of long COVID by tracking 121 people with documented coronavirus infection through their recovery. They measured inflammatory markers in blood plasma at two critical windows: early recovery, defined as the first 90 days after symptom onset, and late recovery, anything beyond that threshold. What they found was a clear biological signature separating those who would go on to develop long COVID from those who recovered cleanly.
People destined for long COVID showed measurably elevated levels of three key inflammatory molecules during early recovery. Tumor necrosis factor-alpha, or TNF-alpha, ran 14 percent higher on average. Interferon gamma-induced protein 10, or IP-10, was 28 percent elevated. Most strikingly, interleukin-6, or IL-6, climbed 29 percent higher in early recovery—and then continued climbing. By late recovery, IL-6 levels in long COVID patients had surged to 44 percent above those in people who had fully recovered.
The study enrolled 121 participants and tracked their progress. At the late recovery checkpoint—a median of 124 days after infection—73 of them, or 60 percent, reported ongoing symptoms. The most common complaints were memory and concentration problems, reported by 57 percent; fatigue, affecting 56 percent; shortness of breath, experienced by 38 percent; and loss of smell, reported by 37 percent. These were not rare edge cases or hypochondriac reports. They were the dominant pattern.
The researchers, led by Michael Peluso, framed their findings as a window into mechanism. The acute phase of COVID-19 triggers a known inflammatory storm—the immune system's response to the virus. But in most people, that inflammation resolves. In long COVID patients, something different appears to happen: the immune system remains activated, continuing to produce inflammatory signals weeks and months after the virus itself has been cleared. This persistent immune activation, the team hypothesized, may be the engine driving the ongoing symptoms that define the condition.
The implications are practical. If persistent inflammation is indeed the culprit, then therapeutic strategies might target those specific inflammatory pathways. The identification of IL-6 and TNF-alpha as particularly robust markers in long COVID patients offers potential drug targets—molecules that could theoretically be dampened or blocked to interrupt the cycle. The researchers emphasized that millions of people worldwide have recovered from acute COVID-19 only to find themselves trapped in this secondary illness, and understanding its biological basis is urgent.
The work remains preliminary. The research paper was posted on medRxiv, a preprint server, meaning it has not yet undergone formal peer review. The sample size, while meaningful, is modest. The findings point toward a biological mechanism but do not yet prove causation or guarantee that targeting these inflammatory markers will actually help patients. Still, for a condition that has confounded medicine and left its sufferers searching for answers, the work represents a concrete step: a measurable biological difference, a named pathway, a direction for further investigation.
Citations marquantes
Persistent immune activation may be associated with ongoing symptoms following COVID-19. Further characterization of these processes might identify therapeutic targets for those experiencing long COVID.— Michael Peluso and colleagues, Mount Sinai and UCSF researchers
A better understanding of these pathogenic processes is critical for identifying therapies to treat and/or prevent this condition among the millions of individuals who have recovered from acute SARS-CoV-2 infection.— The research team
Envie de l'histoire complète ?
Lire l'original sur News-Medical.net ↗
Health & Medicine